The Surgery as Gatekeeper: Building a Primary-Care Route for CRISPR Questions in 2026

For most of the past decade, CRISPR has been discussed in Britain as a specialist concern: a matter for research ethics committees, haematology centres, clinical genetics services and, occasionally, select committees. That framing is now under strain. As licensed somatic gene-editing therapies move into limited NHS use and clinical trials recruit more openly, questions about CRISPR are beginning to surface in ordinary general-practice consultations. The patient may be a parent who has read about a new treatment, a young adult with sickle cell disease who wants to know whether a referral is possible, or someone who has bought a direct-to-consumer genetic test and is unsure what the results mean. The surgery is becoming a gatekeeper by default.

The problem is that general practice has not been designed for this role. CRISPR therapies remain few, highly specialised and tightly governed. Yet the first question a patient asks is rarely technical. It is practical: am I eligible, where would I go, and who decides? If primary care cannot answer that question sensibly, the risk is not merely delay. It is a widening gap between specialist innovation and public understanding, with patients left to navigate claims, waiting lists and private offerings on their own.

Why the questions are arriving now

Three developments are pushing gene editing into primary-care conversation. First, the number of UK patients treated with licensed CRISPR-based therapies remains small, but the existence of such treatments has changed public expectations. A therapy that was once described as futuristic is now part of the NHS lexicon, even where access is restricted. Second, clinical trial activity in the UK has become more visible. Patients increasingly arrive with a study name, a hospital trust or a news article rather than a clear clinical question. Third, consumer genomics has made genetic information more familiar. A patient may present with a variant report that has no bearing on NHS eligibility, but which has prompted a genuine concern about inherited disease.

None of this means that every GP needs to become a gene-editing specialist. It does mean that primary care needs a reliable way to distinguish a routine question from a referral-worthy one, and to direct patients towards trustworthy information when no referral is appropriate.

What GPs are actually being asked

The questions tend to fall into four groups. The first is eligibility: whether a named CRISPR therapy is available on the NHS for a particular condition, and what the patient must do to be considered. The second is trial participation: how to find a legitimate UK study, what enrolment involves and whether participation would affect ordinary care. The third is heritability: whether an edit would be passed on, or whether a somatic treatment has implications for relatives. The fourth is data and insurance: what happens to genetic information, and whether a CRISPR trial or test could affect insurance or employment.

These are not purely medical questions. They are navigational, ethical and administrative at the same time. A GP may be able to manage the clinical background while lacking the pathways to answer the rest. That is the referral gap in its most practical form: not a shortage of specialist capacity alone, but a shortage of signposting at the point of first contact.

The referral gap in practice

In the current NHS landscape, CRISPR therapies sit within specialised commissioning and a small number of designated centres. Referral routes are condition-specific and often depend on haematology, immunology or clinical genetics. This creates a familiar problem for general practice. The patient does not know which route applies; the GP may not know whether a referral would be accepted; and the specialist centre may receive enquiries that are either premature or misdirected.

There is also a resource asymmetry. A specialist team can maintain a detailed view of eligibility criteria, trial status and aftercare requirements. A GP surgery cannot. Expecting every practice to keep pace with a moving field is unrealistic. The better model is not universal expertise but a clear escalation route: a named genomics or specialist liaison contact, a short triage checklist and a directory of active pathways that is maintained at regional level.

A surgery-level pathway worth testing

A workable primary-care pathway would begin with a simple distinction. Is the patient asking about an NHS-funded treatment, a clinical trial, a private service or a consumer test? Each requires a different response. For NHS treatment, the practice needs condition-specific referral criteria and a route into the relevant specialist service. For trials, it needs a curated UK directory and a warning against paying for trial-related assessments. For private services, it needs neutral information about regulatory status and the limits of what can be offered in the UK. For consumer tests, it needs a route to clinical genetics where results suggest genuine risk.

The pathway would also need red flags. A patient with rapid clinical deterioration should not be diverted into a discussion about gene editing. A patient considering a heritable intervention should be counselled about the difference between somatic and germline editing, and referred appropriately. A patient presenting with a commercial offer should be advised to check whether the provider is regulated by the Human Fertilisation and Embryology Authority or the Medicines and Healthcare products Regulatory Agency, as applicable.

The training question

Training should be modest and targeted. Most GPs do not need a deep technical briefing on CRISPR mechanisms. They need a short, regularly updated module covering what licensed therapies exist, what specialised services accept referrals, how to discuss uncertainty, and where to find plain-English patient resources. This could sit within existing genomics education rather than as a separate CRISPR curriculum. The Royal College of General Practitioners and NHS England have a role in making such material visible and quick to use.

The plain-English test

Ultimately, the measure of a good primary-care pathway is whether a patient leaves the surgery with a clearer next step. That may be a referral, a signpost to a specialist service, a recommendation to discuss the issue with clinical genetics, or simply a better understanding that no licensed CRISPR treatment exists for their condition in 2026. Each of those outcomes is better than a vague promise to look into it.

CRISPR will not transform general practice overnight. But the questions are already arriving. The NHS should decide now whether the surgery is to be an informed gateway or an accidental bottleneck.